GSK Plc halted a trial following positive results for an oral antibiotic to treat complicated urinary tract infections that could replace an intravenous medicine that is typically used. The ...

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US regulatory authorities to move the treatment forward in 2025. GSK and Spero ...

Shares of Spero Therapeutics gained after the company and GSK ended their trial for a treatment for complicated urinary tract infections early after it met its primary endpoint. The stock more ...

GSK already scores pretty well among the top 14 pharma companies when it comes to R&D efficiency – ranking third behind Pfizer and Novartis in an analysis of R&D productivity published last year ...

GSK chief executive Andrew Witty told investors yesterday that Advair/Seretide sales are likely to continue to decline, although he insisted that the company is starting to see "some recovery in ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Image credit: fizkes / Shutterstock. GSK and Spero Therapeutics’ Phase III trial of their oral antibiotic for complicated urinary tract infections (cUTI) will end early after successfully meeting its ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

At close: May 30 at 4:00:02 PM EDT ...

Perodua has filed a trademark application for QV-E name and logo with the Intellectual Property Corporation of Malaysia (MyIPO), as sighted by local automotive news site CarPlus. The QV-E logo ...